Seattle-based biotech Ozette Technologies has raised a $26 million Series A round led by Madrona Venture Group.
Ozette, which uses machine learning to analyze immune system data, said in a release the funding, announced Thursday, will help the company grow and expand its capabilities. The company also said it is developing an immunology lab for partners to use Ozette's technology.
“Ozette’s technology alleviates partners from labor intensive, manual analysis methods and propels us towards a future with integrated, searchable immune data,” Ali Ansary, CEO and co-founder of Ozette, said in a release. “We’ve engineered a machine learning-based computational platform that completes months of analysis work in a matter of days, and we’re working on reducing that to minutes."
On its website, Ozette has open roles in data science, product and engineering.
Ozette was founded in 2020. According to Ozette's website, the company's technology discovers and annotates cell populations, and Ozette is looking to work with those in immune research. The company spun out of the Fred Hutchinson Cancer Center, where Ansary holds a part-time clinical appointment, and Ozette was incubated at the Allen Institute for AI.
Ozette has more than 25 full-time employees and raised a $6 million seed round in February 2021.
Seattle-based Madrona has invested in multiple local tech heavyweights, including Amazon, Apptio and Redfin. Cercano Management, formerly Vulcan Capital, Microsoft’s venture fund M12, Alexandria Venture Investments, OCV Partners and Duke University all participated in Ozette's Series A round.
“Ozette’s prescient technology is realizing the future of better healthcare today with unprecedented vision, speed, and invaluable context to unlock how our immune system responds to adversity,” Matt McIlwain, managing director at Madrona, said in a release. “This funding is a testament to the Ozette team and mission, the unique position they hold in the market, and the immense confidence from the industry as they rapidly scale their work."
